← ZhuZhou QianJin Pharmaceutical overview

ZhuZhou QianJin Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ZhuZhou QianJin Pharmaceutical Co Ltd (600479.CG)

Q3 202620 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

August 202620 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

Latest20 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.